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Abstract 
Objectives To assess risk factors for a first thrombotic event in confirmed antiphospholipid (aPL) antibody carriers and 
to evaluate the efficacy of prophylactic treatments. 
Methods Inclusion criteria were age 18–65 years, no history of thrombosis and two consecutive positive aPL results. 
Demographic, laboratory and clinical parameters were collected at enrolment, once a year during the follow-up and at 
the time of the thrombotic event, whenever that occurred. 
Results 258 subjects were prospectively observed between October 2004 and October 2008. The mean±SD follow-up 
was 35.0±11.9 months (range 1–48). A first thrombotic event (9 venous, 4 arterial and 1 transient ischaemic attack) 
occurred in 14 subjects (5.4%, annual incidence rate 1.86%). Hypertension and lupus anticoagulant (LA) were 
significantly predictive of thrombosis (both at p<0.05) and thromboprophylaxis was significantly protective during 
high-risk periods (p<0.05) according to univariate analysis. Hypertension and LA were identified by multivariate 
logistic regression analysis as independent risk factors for thrombosis (HR 3.8, 95% CI 1.3 to 11.1, p<0.05, and HR 3.9, 
95% CI 1.1 to 14, p<0.05, respectively). 
Conclusions Hypertension and LA are independent risk factors for thrombosis in aPL carriers. Thromboprophylaxis in 
these subjects should probably be limited to high-risk situations. 
 
Introduction 
It is unclear if persistent antiphospholipid (aPL) antibodies in the blood are a risk factor for a first thrombotic event, and 
consequently guidelines have yet to be established regarding antithrombotic prophylaxis in these subjects. 
Retrospective,1-4 case–control5–12 and cross-sectional13, 14 studies with different designs, patient selection criteria, aPL 
profiles and risk factors have produced contradictory results. We recently conducted a large retrospective 
study15 exclusively focused on carriers with confirmed aPL positivity. Our results showed that hypertension and 
medium/high titres of IgG anticardiolipin antibodies (aCL) are independent predictors of thrombosis. Long-term 
thromboprophylaxis management and management during high-risk periods were, moreover, found to be independent 
protective factors against thrombosis only when considered together but, when analysed separately, none was protective 
against thrombosis. 
Some prospective studies have likewise failed to produce reliable results since patients with vascular antiphospholipid 
syndrome (APS) and carriers of aPL were considered together.16–18 The aim of the present study was to assess risk 
factors for a first thrombotic event in aPL carriers with at least two consecutive positive test results no less than 12 
weeks apart, and to evaluate the efficacy of primary prophylactic treatments. 
Methods 
Study population 
The study concentrated on aPL carriers attending 11 rheumatology centres, all belonging to the APS Study Group of the 
Italian Society of Rheumatology network. The study population was selected from subjects tested for aPL for one or 
more of the following reasons: previous pregnancy morbidity, systemic lupus erythematosus (SLE) or other 
autoimmune diseases, familiar aPL or APS, before starting oral contraceptive or hormone replacement therapy, 
prolonged activated partial thromboplastin time and biologically false-positive tests for syphilis. The clinical inclusion 
criteria were age 18–65 years and no history of any type of vascular thrombosis. Laboratory criteria for inclusion were 
at least two consecutive positive results for the same aPL antibody(ies) including lupus anticoagulants (LAs) and/or 
IgG/IgM aCL and/or IgG/IgM anti-β2-glycoprotein I (anti-β2GPI) carried out no less than 12 weeks apart.19 Women 
with APS-related pregnancy morbidity, classified in accordance with the Sydney classification criteria for APS,19 were 
also included. Ninety-seven patients participating in the retrospective study15 were also enrolled in the current one. 
Clinical and laboratory parameters (tables 1 and 2) were collected at enrolment and once a year during the follow-up 
period and whenever a thrombotic event occurred. 
The type of prophylactic treatment employed, such as long-term (ie, continuous use of) low-dose aspirin (LDA, 100 mg), long-term 
warfarin or LDA ± heparin administered during high-risk periods (pregnancy/puerperium, immobilisation and surgery), was 
recorded. Long-term LDA was initiated arbitrarily for the following reasons: SLE or other autoimmune diseases, obstetric APS, 
thrombocytosis and LA positivity. Warfarin was administered as prophylactic treatment for high-risk conditions such as pulmonary 
hypertension in connective tissue diseases. Drug compliance was monitored on the basis of self-reports by participants. The number 
of patients who withdrew and the side effects of prophylactic treatment were also registered. Subjects were withdrawn from the study 
when a vascular thrombosis, defined in accordance with the last consensus paper,19 took place. In accordance with the Sydney 
Consensus Conference Criteria,19 transient ischaemic attacks (TIAs) were considered falling ‘within the spectrum of thrombosis’. 
aPL detection 
aCL and anti-β2GPI of IgG and IgM isotypes were determined in five centres by home-made ELISA procedures. In accordance with 
the Sydney update of the classification criteria for APS,19the cut-off values for medium/high titres for aCL as well as for anti-β2GPI 
antibodies were calculated using the 99th percentile obtained by testing age-matched healthy subjects. These ranged between 6.2 and 
21.0 immunoglobulin G phospholipid units (GPL) for IgG aCL, between 17.4 and 21.0 immunoglobulin M phospholipid units (MPL) 
for IgM aCL, between 2.1 and 12.1 Units for IgG anti-β2GPI, and between 8.5 and 13.9 Units for IgM anti-β2GPI antibodies. The 
other six centres assessed IgG/IgM aCL and IgG/IgM anti-β2GPI antibodies using commercial kits following the manufacturers' 
instructions. The cut-off values for medium/high titres ranged between 10 and 40 GPL for IgG aCL, between 10 and 40 MPL for IgM 
aCL, between 10 and 20 Units for IgG anti-β2GPI, and between 10 and 20 Units for IgM anti-β2GPI antibodies. LA was determined 
by multiple coagulation tests using platelet-poor plasma samples following internationally accepted guidelines.20 
Statistical analyses 
Univariate analysis was performed to assess the association between thrombotic events and risk factors using the Pearson, χ2 and 
Fisher exact tests. A Kaplan–Meier survival analysis and the log-rank test were carried out to analyse the cumulative incidence of 
events in the groups of patients with and without potential risk factors. The McNemar test was employed in the patients who 
developed thrombosis to evaluate if there was a significant difference between the distribution of risk factors found at the time of 
enrolment and at the time of the thrombotic event. Multivariate survival analysis was performed using the proportional hazards 
model (Cox model) to identify significant independent factors adjusted for the potential confounding risk factors able to predict a 
thrombotic event. The forward conditional techniques were used to find the final model. The results are expressed as HRs with 95% 
CI. 
Results 
A cohort of 258 Caucasian confirmed aPL carriers (223 women and 35 men, mean±SD age 40.9±11.1 years, range 18–65) without a 
history of thrombosis were prospectively evaluated between 15 October 2004 and 15 October 2008 for a mean±SD follow-up of 
35.0±11.9 months (range 1–48). Their baseline clinical characteristics and risk factors for thrombosis as well as the prophylactic 
treatments are shown in table 1. High-risk situations (surgery/immobilisation, pregnancy/puerperium) occurring during the follow-up 
period are also specified. Although none of the participants developed serious adverse events such as major bleeding episodes during 
prophylaxis, three patients discontinued long-term prophylaxis for personal reasons. Forty-nine of the patients presented with 
pregnancy morbidity at enrolment and four presented with pregnancy morbidity during the follow-up; aPLs were detected in all of 
these women at the time the diagnosis was formulated and then, according to the study protocol, once a year. Twenty-nine (54.7%) of 
the 53 women with obstetric APS took LDA prophylaxis continuously, beginning at the presentation of pregnancy morbidity. The 
results of the baseline autoantibody assays are shown in table 2. During the follow-up period 189 subjects (73.3%) maintained at least 
one aPL antibody at medium/high titre while 69 (26.7%) became negative or positive to a different antibody. 
First thrombotic event 
Fourteen patients (5.4% of the study population; 10 women and 4 men with a mean±SD age of 39.9±11.7 years, range 23–60) had a 
first thrombotic event (9 venous thromboses (64.3%), 4 arterial thromboses (28.6%), 1 TIA (7.1%)) after a mean±SD follow-up of 
21.4±18.3 months (range 1–47.6). The thrombosis incidence rate was 1.86 per 100 patients per year. The clinical and laboratory 
features of these patients at baseline and at the time of the thrombotic event are shown in tables S1 and S2 in the online supplement. 
Clinical and laboratory profiles (including risk factors for thrombosis) at the time of the thrombotic event were not significantly 
different from those recorded at baseline. 
Analysis of risk factors for thrombosis 
All demographic, clinical and laboratory characteristics, including risk factors for thrombosis, were evaluated by univariate analysis 
(tables 1 and 2). Hypertension and LA were significantly associated with thrombosis (both p<0.05). As shown in figure 1, Kaplan–
Meier survival analysis provided similar results: the cumulative incidence of thromboembolic events was significantly higher in 
patients with hypertension (p<0.01) and LA (p<0.05). Finally, analysis of the relationship between each variable (hypertension, 
medium/high IgG aCL levels and prophylaxis) and venous/arterial thrombosis or TIA, considered separately, uncovered no 
significant association. 
Thromboembolic events were significantly reduced only when antithrombotic prophylaxis was administered in high-risk situations 
(OR 0.1, 95% CI 0.01 to 0.9, p<0.05). Continuous prophylaxis was not associated with a reduction in thromboembolic events. 
Multivariate analysis adjusted for potential confounding risk factors such as age, sex, aPL antibodies, hypertension, autoimmune 
diseases, pregnancy/puerperium, smoking, hypercholesterolaemia, body mass index, pill/hormone replacement therapy or diabetes 
mellitus indicated that only hypertension (HR 3.8, 95% CI 1.3 to 11.1, p<0.05) and LA (HR 3.9, 95% CI 1.1 to 14, p<0.05) were 
independent risk factors for thrombosis. 
Discussion 
The most important finding of this study is that hypertension and LA positivity are two independent risk factors for 
thrombosis in aPL carriers. 
The finding that hypertension is a risk factor for thrombosis is not a novel one as we reported this in our previous 
retrospective study on aPL carriers.15 An association between hypertension and arterial thrombosis was also reported by 
one cross-sectional13 and one prospective study17 aiming to identify the predictors of vascular events in cohorts of both 
APS patients and aPL carriers. Nor is LA positivity a novel risk factor for thrombosis, as three case–control studies on 
aPL carriers5,6,12 reported that it is associated with arterial and/or venous thrombosis. The present work is different from 
the others because it is the first prospective study focusing on an entirely homogeneous cohort including only confirmed 
aPL carriers without a history of thrombosis who underwent three antibody tests (LA, aCL and anti-β2GPI antibodies). 
In agreement with previously reported findings,1,15 pregnancy was not associated with thrombosis in our patients. This 
is probably due to the fact that most of the pregnant women being studied here were protected by LDA ± low molecular 
weight heparin prophylactic treatment. 
In accordance with international guidelines, all participating centres strongly advised aPL carriers to avoid taking 
contraceptive pills or hormone replacement therapy. As a consequence, the small number of women studied here taking 
those drugs probably explains why no association was found with thrombotic events. 
Finally, the number of thrombotic events was rather low (incidence rate 1.86% per 100 patients per year) and similar to 
that reported in other studies1–3,7,8,13,16 and by our own retrospective study.15 Primary prophylaxis in high-risk situations 
was found to be a significant protective factor against thrombosis according to univariate analysis. Similar results were 
obtained in a prospective study17 which reported no thrombotic events in 178 aPL carriers using thromboprophylaxis in 
high-risk situations. 
We can therefore conclude that hypertension and LA were independent risk factors for thrombosis in this prospective 
cohort study on confirmed aPL carriers with no history of thrombosis. Thromboprophylaxis should probably be limited 
in these patients to high-risk situations. The fact that there was no central laboratory for aPL testing, which certainly 
represents a missed opportunity, and the short follow-up period can be considered limitations of the study. Long-term 
prospective studies using a central reference laboratory for all the participating centres are warranted. 
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Table 1 
Baseline clinical characteristics of antiphospholipid carriers, prophylaxis and the thrombosis rate in the study 
subjects 
Clinical characteristics Prevalence 
Thrombotic events 
No Yes 
Systemic autoimmune diseases 177/258 (68.6%) 167/244 (68.4%) 10/14 (71.4%) 
Systemic lupus erythematosus  70/258 (27.1%) 66/244 (27.0%) 4/14 (28.6%) 
Others * 107/258 (41.5%) 101/244 (41.4%) 6/14 (42.9%) 
Clinical characteristics Prevalence 
Thrombotic events 
No Yes 
No systemic autoimmune diseases 81/258 (31.4%) 77/244 (31.6%) 4/14 (28.6%) 
Women who were or had been pregnant 144/223 (64.6%) 140/213 (65.7%) 4/10 (40.0%) 
Obstetric antiphospholipid syndrome (APS) † 49/144 (34.0%) 46/140 (32.9%) 3/4 (75.0%) 
No obstetric APS  95/144 (66.0%) 94/140 (67.1%) 1/4 (25.0%) 
Thrombophylic risk factors 
Pregnancy/puerperium  26/155 (16.8%)‡ 24/147 (16.3%) 2/8 (25.0%) 
Smoking  60/258 (23.3%) 58/244 (23.8%) 2/14 (14.3%) 
Hypertension (systolic  >140, diastolic >90) 47/258 (18.2%) 41/244 (16.8%) 6/14 (42.9%)§ 
Hypercholesterolaemia ( >240 mg/dl) 22/258 (8.5%) 21/244 (8.6%) 1/14 (7.1%) 
BMI  >85th percentile 15/258 (5.8%) 15/244 (6.1%) 0/14 (0.0%) 
Pill/hormone replacement therapy  12/223 (5.4%) 12/213 (5.6%) 0/10 (0.0%) 
Diabetes mellitus  5/258 (1.9%) 5/244 (2.0%) 0/14 (0.0%) 
Prophylaxis 
Long-term ¶ 140/258 (54.3%) 132/244 (54.1%) 8/14 (57.1%) 
Only during risk situations ** 68/98 (69.4%) 66/93 (71.0%) 2/5 (40.0%) 
↵* 50 undifferentiated connective tissue disease, 32 autoimmune thyroiditis, 9 rheumatoid arthritis, 7 autoimmune 
thrombocytopenia, 7 vasculitis, 6 systemic sclerosis, 6 Sjögren's syndrome and 15 other types of autoimmune diseases 
(36 patients had contemporaneously more than one autoimmune diseases). 
↵† 32 fetal losses (type a), 11 premature births (type b) and 13 early abortions (type c) (7 of these women had 
contemporaneously more than one type of pregnancy morbidity). 
↵‡ Women of childbearing age. 
↵§ Statistically significant (p<0.05). 
↵¶ 138 with low-dose aspirin (LDA) and 2 with warfarin. 
↵** 15 surgery/immobilisation (14 with low molecular weight heparin, 1 with warfarin), 53 pregnancy/puerperium (25 
with LDA, 12 with low molecular weight heparin and 16 with both), 30 events (9 surgery/immobilisation and 21 











IgG aCL medium/high titres 101/258 (39.1%) 95/244 (38.9%) 6/14 (42.9%) 
IgM aCL medium/high titres 74/258 (28.7%) 69/244 (28.3%) 5/14 (35.7%) 
IgG anti-β2GPI medium/high titres 104/258 (40.3%) 99/244 (40.6%) 5/14 (35.7%) 
IgM anti-β2GPI medium/high titres 79/258 (30.6%) 74/244 (30.3%) 5/14 (35.7%) 




aPL antibody category I 130/258 (50.4%) 121/244 (49.6%) 9/14 (64.3%) 
aPL antibody category II 128/258 (49.6%) 123/244 (50.4%) 5/14 (35.7%) 
Antinuclear antibodies 163/258 (63.2%) 154/244 (63.1%) 9/14 (64.3%) 
Anti-double strand DNA antibodies 33/255 (26.4%) 31/241 (12.9%) 2/14 (14.3%) 
Anti-extractable nuclear antigen antibodies 52/258 (12.9%) 48/244 (19.7%) 4/14 (28.6%) 
↵* Statistically significant (p<0.05). 
aCL, anticardiolipin antibodies; anti-β2GPI, anti-β2-glycoprotein I antibodies. 
 
Figure 1 
Kaplan–Meier survival analysis and log rank test showing that the cumulative incidence of thrombotic events 
was significantly higher in patients with hypertension (p<0.01) and lupus anticoagulant (p<0.05). 
 
